On Thursday, Exelixis received a positive adjustment to its Relative Strength (RS) Rating, from 63 to 74.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily identifies price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks typically have an 80 or better RS Rating as they launch their biggest runs. See if Exelixis can continue to show renewed price strength and clear that threshold.
Exelixis is trying to complete a consolidation with a 49.62 buy point. See if the stock can clear the breakout price in heavy trading.
Exelixis reported negative growth for both sales and earnings last quarter.
The company holds the No. 33 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
